M&T Bank Corp Decreases Position in Becton, Dickinson and Company (NYSE:BDX)

M&T Bank Corp reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 33.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,138 shares of the medical instruments supplier’s stock after selling 27,685 shares during the period. M&T Bank Corp’s holdings in Becton, Dickinson and Company were worth $13,201,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Sapient Capital LLC acquired a new position in Becton, Dickinson and Company during the fourth quarter worth approximately $1,295,000. Vest Financial LLC boosted its stake in Becton, Dickinson and Company by 27.5% during the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after purchasing an additional 22,207 shares during the period. M. Kulyk & Associates LLC grew its position in Becton, Dickinson and Company by 5.1% during the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock worth $4,302,000 after purchasing an additional 809 shares during the last quarter. SG Americas Securities LLC increased its stake in Becton, Dickinson and Company by 69.4% in the fourth quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after purchasing an additional 6,190 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock valued at $174,122,000 after buying an additional 7,790 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, Barclays raised their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $280.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $5.67 during trading on Friday, hitting $234.68. 1,722,353 shares of the stock were exchanged, compared to its average volume of 1,291,373. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The company has a market cap of $67.80 billion, a PE ratio of 51.69, a P/E/G ratio of 1.93 and a beta of 0.45. The company has a fifty day moving average price of $238.45 and a two-hundred day moving average price of $240.53. The company has a current ratio of 1.41, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the business posted $2.86 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.